Announcements Trials
Browse Landscape

Phase

Phase 1 17Phase 2 10Phase 1/2 6Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 6Terminated 4Recruiting 3Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 3NIH 2INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 2Genitourinary 2Other hematologic neoplasm 1Gynecologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × talazoparib × Clear all
NCT04019327 2025-12-15

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
16 enrolled
Genitourinary

Prostatic Neoplasms

NCT04497116 2025-10-21

TRESR

Repare Therapeutics

Phase 1/2 Completed
276 enrolled 33 charts
Other solid neoplasm

Advanced Solid Tumor

NCT04337970 2025-05-28

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
23 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02878785 2023-03-29

1565GCC

University of Maryland, Baltimore

Phase 1/2 Completed
25 enrolled 6 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02116777 2021-03-26

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

National Cancer Institute (NCI)

Phase 1/2 Completed
40 enrolled 32 charts
CNS

Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
9 enrolled 11 charts
BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡